Proposed Updates for Developing, Implementing, and Evaluating Infection Control Programs for Viral Hemorrhagic Fevers, Andes Virus, and Nipah Virus: Appendix A, 14074-14075 [2024-03784]

Download as PDF 14074 Federal Register / Vol. 89, No. 38 / Monday, February 26, 2024 / Notices This feature is no longer technologically supported. OGE proposes to discontinue use of the nonaccessible PDF version and instead add additional blank lines to the 508 compliant PDF version. Going forward, therefore, OGE seeks approval only for two versions of the form—the 508 compliant PDF version and the Excel version. OMB Control Number: 3209–0006. Type of Information Collection: Extension of a currently approved collection. Type of Review Request: Regular. Affected public: Prospective Government employees, including special Government employees, whose positions are designated for confidential disclosure filing and whose agencies require that they file new entrant confidential disclosure reports prior to assuming Government responsibilities. Estimated Annual Number of Respondents: 31,654. Estimated Time per Response: 3 hours. Estimated Total Annual Burden: 94,962 hours. Request for Comments: OGE is publishing this first round notice of its intent to request paperwork clearance renewal for the OGE Form 450. Public comment is invited specifically on the need for and practical utility of this information collection, the accuracy of OGE’s burden estimate, the enhancement of quality, utility and clarity of the information collected, and the minimization of burden (including the use of information technology). OGE specifically seeks comments on whether the proposed changes will change the burden of completing the form. Comments received in response to this notice will be summarized for, and may be included with, the OGE request for extension of OMB paperwork approval. The comments will also become a matter of public record. Approved: February 20, 2024. Shelley K. Finlayson, Acting Director, U.S. Office of Government Ethics. [FR Doc. 2024–03813 Filed 2–23–24; 8:45 am] khammond on DSKJM1Z7X2PROD with NOTICES BILLING CODE 6345–03–P VerDate Sep<11>2014 16:23 Feb 23, 2024 Jkt 262001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2024–0015] Proposed Updates for Developing, Implementing, and Evaluating Infection Control Programs for Viral Hemorrhagic Fevers, Andes Virus, and Nipah Virus: Appendix A Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) announces the opening of a docket to obtain comment on Draft Proposed Updates for Viral hemorrhagic fevers, Andes virus, and Nipah virus: Appendix A (‘‘Draft Updates: Appendix A’’). The updated recommendations in the Draft Updates: Appendix A are intended for use by frontline healthcare personnel, as well as infection control personnel and other persons responsible for developing, implementing, and evaluating infection control programs for healthcare settings across the continuum of care. DATES: Written comments must be received on or before April 26, 2024. ADDRESSES: You may submit comments, identified by Docket No. CDC–2024– 0015 by either of the methods listed below. Do not submit comments by email. CDC does not accept comments by email. • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: Healthcare Infection Control Practices Advisory Committee (HICPAC) Secretariat, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H16–3, Atlanta, Georgia 30329, Attn: Docket Number CDC–2024–0015. Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to https://regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Laura Wells, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H16–2, Atlanta, SUMMARY: PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 Georgia 30329; Telephone: (404) 639– 4000. SUPPLEMENTARY INFORMATION: Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to Draft Updates: Appendix A. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. Do not submit comments by email. CDC does not accept comment by email. Background The Draft Updates: Appendix A, located in the ‘‘Supporting and Related Material’’ tab of the docket, updates the recommendations in Appendix A of the Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007) on the type and duration of isolation precautions for Viral hemorrhagic fevers, Andes virus, and Nipah virus. The Draft Updates: Appendix A provides recommendations to prevent transmission, focusing primarily on types and durations of precautions available to frontline healthcare personnel. The recommendations are being updated to include additional viruses with potential for importation to the United States. The Draft Updates: Appendix A is intended for use by frontline healthcare personnel, as well as infection control personnel and other persons responsible for developing, implementing, and evaluating infection control programs for healthcare settings across the continuum of care. Once the Draft Updates: Appendix A is finalized, the corresponding content in Appendix A of the Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007) will be updated on the CDC E:\FR\FM\26FEN1.SGM 26FEN1 Federal Register / Vol. 89, No. 38 / Monday, February 26, 2024 / Notices Infection Control website (https:// www.cdc.gov/infectioncontrol/ guidelines/isolation/appendix/index. html). The updated recommendations in Draft Updates: Appendix A are informed by review and consideration of available literature on transmission principles and infection prevention and control practices for each virus. Draft recommendations were presented to the Healthcare Infection Control Practices Advisory Committee (HICPAC), whose feedback was incorporated into the finalized draft recommendations. HICPAC is a Federal advisory committee appointed to provide advice and guidance to HHS and CDC regarding the practice of infection control and strategies for surveillance, prevention, and control of healthcareassociated infections, antimicrobial resistance, and related topics in United States healthcare settings. HICPAC includes, but is not limited to, representatives with expertise in public health, infectious diseases, and infection prevention and control. HICPAC also includes ex officio members who represent regulatory and other Federal agencies and liaison representatives from professional societies. CDC is seeking comments on the Draft Updates: Appendix A. Please provide references to new evidence and justification to support any suggested revisions or additions. This Draft Updates: Appendix A is not a Federal rule or regulation. Noah Aleshire, Chief Regulatory Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–03784 Filed 2–23–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention khammond on DSKJM1Z7X2PROD with NOTICES [Docket No. CDC–2024–0014] Draft Infection Control in Healthcare Personnel: Epidemiology and Control of Selected Infections Transmitted Among Healthcare Personnel and Patients: Cytomegalovirus and Parvovirus B19 Sections and Draft Source Control Definition Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), in the SUMMARY: VerDate Sep<11>2014 16:23 Feb 23, 2024 Jkt 262001 Department of Health and Human Services (HHS), announces the opening of a docket to obtain comment on the Draft Infection Control in Healthcare Personnel: Epidemiology and Control of Selected Infections Transmitted Among Healthcare Personnel and Patients: Cytomegalovirus and Parvovirus B19 Sections (‘‘Draft Guideline: Cytomegalovirus and Parvovirus B19 Sections’’), and on the accompanying Draft ‘‘Source Control’’ Definition adapted for Infection Control in Healthcare Personnel to be in the ‘‘Terminology’’ Appendix. The updated recommendations in the Draft Guideline: Cytomegalovirus and Parvovirus B19 Sections are intended for use by the leaders and staff of Occupational Health Services (OHS), as further provided herein. These updated recommendations will help facilitate the provision of occupational infection prevention and control services to healthcare personnel (HCP) who have been exposed or infected and may be contagious to others in the workplace. DATES: Written comments must be received on or before April 26, 2024. ADDRESSES: You may submit comments, identified by Docket No. CDC–2024– 0014 by either of the methods listed below. Do not submit comments by email. CDC does not accept comments by email. • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Mail: Healthcare Infection Control Practices Advisory Committee (HICPAC) Secretariat, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H16–3, Atlanta, Georgia 30329, Attn: Docket Number CDC–2024–0014. Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to https://regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Laura Wells, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H16–2, Atlanta, Georgia 30329; Telephone: (404) 639– 4000. SUPPLEMENTARY INFORMATION: Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 14075 data related to the Draft Guideline: Cytomegalovirus and Parvovirus B19 Sections, and the accompanying Draft ‘‘Source Control’’ Definition. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. Do not submit comments by email. CDC does not accept comments by email. Background The Draft Guideline: Cytomegalovirus and Parvovirus B19 Sections, located in the ‘‘Supporting & Related Material’’ tab of the docket, updates the Guideline for infection control in health care personnel, 1998, Part E: Epidemiology and Control of Selected Infections Transmitted Among Health Care Personnel and Patients, and its corresponding recommendations in Part II of the 1998 Guideline: ‘‘3. Cytomegalovirus;’’ and ‘‘11. Parvovirus.’’ The accompanying Draft ‘‘Source Control’’ Definition adapted for Infection Control in Healthcare Personnel to be in the ‘‘Terminology’’ Appendix (https://www.cdc.gov/ infectioncontrol/guidelines/healthcarepersonnel/terminology.html) is also located in the ‘‘Supporting & Related Material’’ tab of the docket. The 1998 Guideline provided information and recommendations for Occupational Health Services (OHS) of healthcare facilities and systems on the prevention of transmission of infectious diseases among healthcare personnel (HCP) and patients and can be found at https:// stacks.cdc.gov/view/cdc/11563. As described in the Executive Summary of this guideline (https:// www.cdc.gov/infectioncontrol/ guidelines/healthcare-personnel/execsummary.html), in this document, ‘‘OHS’’ is used synonymously with ‘‘Employee Health,’’ ‘‘Employee Health Services,’’ ‘‘Employee Health and Safety,’’ ‘‘Occupational Health,’’ and other such programs. OHS refers to the E:\FR\FM\26FEN1.SGM 26FEN1

Agencies

[Federal Register Volume 89, Number 38 (Monday, February 26, 2024)]
[Notices]
[Pages 14074-14075]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-03784]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2024-0015]


Proposed Updates for Developing, Implementing, and Evaluating 
Infection Control Programs for Viral Hemorrhagic Fevers, Andes Virus, 
and Nipah Virus: Appendix A

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC) in the 
Department of Health and Human Services (HHS) announces the opening of 
a docket to obtain comment on Draft Proposed Updates for Viral 
hemorrhagic fevers, Andes virus, and Nipah virus: Appendix A (``Draft 
Updates: Appendix A''). The updated recommendations in the Draft 
Updates: Appendix A are intended for use by frontline healthcare 
personnel, as well as infection control personnel and other persons 
responsible for developing, implementing, and evaluating infection 
control programs for healthcare settings across the continuum of care.

DATES: Written comments must be received on or before April 26, 2024.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0015 by either of the methods listed below. Do not submit comments by 
email. CDC does not accept comments by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Healthcare Infection Control Practices Advisory 
Committee (HICPAC) Secretariat, Division of Healthcare Quality 
Promotion, Centers for Disease Control and Prevention, 1600 Clifton 
Road NE, Mailstop H16-3, Atlanta, Georgia 30329, Attn: Docket Number 
CDC-2024-0015.
    Instructions: All submissions received must include the agency name 
and Docket Number. All relevant comments received will be posted 
without change to https://regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Laura Wells, Division of Healthcare 
Quality Promotion, Centers for Disease Control and Prevention, 1600 
Clifton Road NE, Mailstop H16-2, Atlanta, Georgia 30329; Telephone: 
(404) 639-4000.

SUPPLEMENTARY INFORMATION:

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data related to Draft 
Updates: Appendix A.
    Please note that comments received, including attachments and other 
supporting materials, are part of the public record and are subject to 
public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your 
comment or supporting materials that you consider confidential or 
inappropriate for public disclosure. If you include your name, contact 
information, or other information that identifies you in the body of 
your comments, that information will be on public display. CDC will 
review all submissions and may choose to redact, or withhold, 
submissions containing private or proprietary information such as 
Social Security numbers, medical information, inappropriate language, 
or duplicate/near duplicate examples of a mass-mail campaign. Do not 
submit comments by email. CDC does not accept comment by email.

Background

    The Draft Updates: Appendix A, located in the ``Supporting and 
Related Material'' tab of the docket, updates the recommendations in 
Appendix A of the Guideline for Isolation Precautions: Preventing 
Transmission of Infectious Agents in Healthcare Settings (2007) on the 
type and duration of isolation precautions for Viral hemorrhagic 
fevers, Andes virus, and Nipah virus. The Draft Updates: Appendix A 
provides recommendations to prevent transmission, focusing primarily on 
types and durations of precautions available to frontline healthcare 
personnel. The recommendations are being updated to include additional 
viruses with potential for importation to the United States. The Draft 
Updates: Appendix A is intended for use by frontline healthcare 
personnel, as well as infection control personnel and other persons 
responsible for developing, implementing, and evaluating infection 
control programs for healthcare settings across the continuum of care. 
Once the Draft Updates: Appendix A is finalized, the corresponding 
content in Appendix A of the Guideline for Isolation Precautions: 
Preventing Transmission of Infectious Agents in Healthcare Settings 
(2007) will be updated on the CDC

[[Page 14075]]

Infection Control website (https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/).
    The updated recommendations in Draft Updates: Appendix A are 
informed by review and consideration of available literature on 
transmission principles and infection prevention and control practices 
for each virus. Draft recommendations were presented to the Healthcare 
Infection Control Practices Advisory Committee (HICPAC), whose feedback 
was incorporated into the finalized draft recommendations. HICPAC is a 
Federal advisory committee appointed to provide advice and guidance to 
HHS and CDC regarding the practice of infection control and strategies 
for surveillance, prevention, and control of healthcare-associated 
infections, antimicrobial resistance, and related topics in United 
States healthcare settings. HICPAC includes, but is not limited to, 
representatives with expertise in public health, infectious diseases, 
and infection prevention and control. HICPAC also includes ex officio 
members who represent regulatory and other Federal agencies and liaison 
representatives from professional societies.
    CDC is seeking comments on the Draft Updates: Appendix A. Please 
provide references to new evidence and justification to support any 
suggested revisions or additions. This Draft Updates: Appendix A is not 
a Federal rule or regulation.

Noah Aleshire,
Chief Regulatory Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-03784 Filed 2-23-24; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.